GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial ...

The company's vaccine consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein.

"EC approves GSK’s RSV vaccine for adults aged 50-59 years" was originally created and published by Pharmaceutical Technology ...

Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, ...

From 1 September, the NHS will vaccinate pregnant women from 28 weeks onward, and adults turning 75, shielding these vulnerable individuals from falling ill this winter. Adults aged 75 to 79 will be ...

(Family Features) Even though cooler days may seem far off, now is the best time to plan ahead for a healthy winter. One ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

These vaccines are now available to adults 60 and older. In terms of dosage, the CDC recommends a single dose for individuals over 75.

Vaccines for the Fall and Winter 2024–2025 season are now available. Generally, experts recommend COVID-19 and flu vaccines ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

The FDA cited concerns with the API manufacturing plant including falsifying production records and failing to follow proper ...